311 related articles for article (PubMed ID: 18300808)
1. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases.
Schmitt AM; Riniker F; Anlauf M; Schmid S; Soltermann A; Moch H; Heitz PU; Klöppel G; Komminoth P; Perren A
Am J Surg Pathol; 2008 Mar; 32(3):420-5. PubMed ID: 18300808
[TBL] [Abstract][Full Text] [Related]
2. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin.
Koo J; Mertens RB; Mirocha JM; Wang HL; Dhall D
Mod Pathol; 2012 Jun; 25(6):893-901. PubMed ID: 22388755
[TBL] [Abstract][Full Text] [Related]
3. The expression of TTF1, CDX2 and ISL1 in 74 poorly differentiated neuroendocrine carcinomas.
Lee H; Fu Z; Koo BH; Sheehan CE; Young GQ; Lin J; Patil DT; Yang Z
Ann Diagn Pathol; 2018 Dec; 37():30-34. PubMed ID: 30236546
[TBL] [Abstract][Full Text] [Related]
4. Value of SATB2, ISL1, and TTF1 to differentiate rectal from other gastrointestinal and lung well-differentiated neuroendocrine tumors.
Zhao LH; Chen C; Mao CY; Xiao H; Fu P; Xiao HL; Wang G
Pathol Res Pract; 2019 Jul; 215(7):152448. PubMed ID: 31133441
[TBL] [Abstract][Full Text] [Related]
5. Islet-1 is a sensitive but not entirely specific marker for pancreatic neuroendocrine neoplasms and their metastases.
Graham RP; Shrestha B; Caron BL; Smyrk TC; Grogg KL; Lloyd RV; Zhang L
Am J Surg Pathol; 2013 Mar; 37(3):399-405. PubMed ID: 23348208
[TBL] [Abstract][Full Text] [Related]
6. An algorithmic approach utilizing CK7, TTF1, beta-catenin, CDX2, and SSTR2A can help differentiate between gastrointestinal and pulmonary neuroendocrine carcinomas.
Yu S; Hornick JL; Gonzalez RS
Virchows Arch; 2021 Sep; 479(3):481-491. PubMed ID: 33733343
[TBL] [Abstract][Full Text] [Related]
7. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2.
Hermann G; Konukiewitz B; Schmitt A; Perren A; Klöppel G
Virchows Arch; 2011 Aug; 459(2):147-54. PubMed ID: 21739268
[TBL] [Abstract][Full Text] [Related]
8. PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.
Long KB; Srivastava A; Hirsch MS; Hornick JL
Am J Surg Pathol; 2010 May; 34(5):723-9. PubMed ID: 20414099
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin.
Lin X; Saad RS; Luckasevic TM; Silverman JF; Liu Y
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):407-14. PubMed ID: 18091383
[TBL] [Abstract][Full Text] [Related]
10. NKX6-1 Is a Novel Immunohistochemical Marker for Pancreatic and Duodenal Neuroendocrine Tumors.
Tseng IC; Yeh MM; Yang CY; Jeng YM
Am J Surg Pathol; 2015 Jun; 39(6):850-7. PubMed ID: 25871618
[TBL] [Abstract][Full Text] [Related]
11. Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2.
Panarelli NC; Yantiss RK; Yeh MM; Liu Y; Chen YT
Am J Clin Pathol; 2012 Aug; 138(2):211-22. PubMed ID: 22904132
[TBL] [Abstract][Full Text] [Related]
12. ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin.
Agaimy A; Erlenbach-Wünsch K; Konukiewitz B; Schmitt AM; Rieker RJ; Vieth M; Kiesewetter F; Hartmann A; Zamboni G; Perren A; Klöppel G
Mod Pathol; 2013 Jul; 26(7):995-1003. PubMed ID: 23503646
[TBL] [Abstract][Full Text] [Related]
13. CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors.
La Rosa S; Rigoli E; Uccella S; Chiaravalli AM; Capella C
Virchows Arch; 2004 Sep; 445(3):248-54. PubMed ID: 15517368
[TBL] [Abstract][Full Text] [Related]
14. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
[TBL] [Abstract][Full Text] [Related]
15. IMP3, NESP55, TTF-1 and CDX2 serve as an immunohistochemical panel in the distinction among small-cell carcinoma, gastrointestinal carcinoid, and pancreatic endocrine tumor metastasized to the liver.
Denby KS; Briones AJ; Bourne PA; Spaulding BO; Lu D; Fischer-Colbrie R; Qu Z; Wang HL; Xu H
Appl Immunohistochem Mol Morphol; 2012 Dec; 20(6):573-9. PubMed ID: 22495359
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver.
Yang Z; Klimstra DS; Hruban RH; Tang LH
Am J Surg Pathol; 2017 Jul; 41(7):915-922. PubMed ID: 28498280
[TBL] [Abstract][Full Text] [Related]
17. CDX2, SATB2, GATA3, TTF1, and PAX8 Immunohistochemistry in Krukenberg Tumors.
Chiesa-Vottero A
Int J Gynecol Pathol; 2020 Mar; 39(2):170-177. PubMed ID: 32045390
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors.
Srivastava A; Hornick JL
Am J Surg Pathol; 2009 Apr; 33(4):626-32. PubMed ID: 19065104
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids.
Saqi A; Alexis D; Remotti F; Bhagat G
Am J Clin Pathol; 2005 Mar; 123(3):394-404. PubMed ID: 15716236
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7.
Vang R; Gown AM; Wu LS; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
Mod Pathol; 2006 Nov; 19(11):1421-8. PubMed ID: 16980943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
